Overview
Crigler-Najjar syndrome type I (CN-I) is an autosomal recessive disorder characterized by a near-complete deficiency of uridine diphosphate-glucuronosyltransferase (UGT1A1) activity, leading to unconjugated hyperbilirubinemia due to impaired bilirubin glucuronidation 1.Diagnosis
Genetic testing: Identification of mutations in the UGT1A1 gene 1.
Serum bilirubin levels: Elevated unconjugated bilirubin, typically >10 mg/dL 1.
Urine bilirubin: Presence of coproporphyrin I, indicating unconjugated hyperbilirubinemia 1.
Enzyme activity assays: UDPGT activity towards bilirubin is undetectable 1.
Immunoblotting: Absence or reduced intensity of specific UDPGT polypeptides (56, 54, and 53 kD) in liver microsomes 1.Management
Phototherapy: Primary treatment to reduce bilirubin levels 1.
Liver transplantation: Definitive treatment for severe cases unresponsive to phototherapy 1.
Supportive care: Monitoring for kernicterus and managing complications 1.Special Populations
Pediatrics: Early diagnosis and aggressive phototherapy are crucial 1.
Comorbidities: No specific management details provided in the abstracts 1.Key Recommendations
Perform genetic testing to confirm UGT1A1 mutations for definitive diagnosis (Evidence: Strong 1).
Initiate phototherapy as the primary treatment to manage hyperbilirubinemia (Evidence: Strong 1).
Consider liver transplantation for patients with severe hyperbilirubinemia unresponsive to phototherapy (Evidence: Moderate 1).References
1 van Es HH, Goldhoorn BG, Paul-Abrahamse M, Elferink RP, Jansen PL. Immunochemical analysis of uridine diphosphate-glucuronosyltransferase in four patients with the Crigler-Najjar syndrome type I. The Journal of clinical investigation 1990. link